Cara Therapeutics (NasdaqGM:CARA) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Cara Therapeutics to reach your target.
Hmm, we can't give any reliable projection for Cara Therapeutics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.
None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!
| Advantages | Disadvantages | Neutral |
|---|---|---|
| None. |
|
|
| CARA Price (Cara Therapeutics stock price per share) |
$0.00 | |
| PE Ratio versus Sector | 211% higher than other Healthcare stocks | |
| PE Ratio versus Industry | 9% higher than other Drug Manufacturers - General stocks | |
| Free Cash Flow Jitter | 77% |
No open-market insider buys or sells are recorded for the last 12 months.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
How to read this: what free cash flow is, why earnings matter.
Over the 1 fiscal years from 2012 to 2025 with positive net income, operating cash flow totaled -$5.5 million against net income of $8.4 million, or -0.65 times. Net income was negative in 13 of the 14 years, and those years are left out of the ratio.
In 2025, net income was -$18.2 million and operating cash flow was -$23.5 million, so no ratio is shown for that year.
In 2013, capital expenditures were $0 million, 0.2% of operating cash flow of $2.8 million, which leaves an estimated $2.8 million after capex. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2012 | -6.3 | -6 | not reported | n/a |
| 2013 | -4 | 2.8 | 0 | n/a |
| 2014 | -17.7 | -17.6 | 0 | n/a |
| 2015 | -24.7 | -21.5 | 0 | n/a |
| 2016 | -57.3 | -47.4 | 0.7 | n/a |
| 2017 | -58.1 | -54.8 | 0.1 | n/a |
| 2018 | -74 | -22.3 | 0.1 | n/a |
| 2019 | -106 | -109 | 0 | n/a |
| 2020 | 8.4 | -5.5 | 0.3 | -0.65 |
| 2021 | -88.4 | -60.1 | 0 | n/a |
| 2022 | -85.5 | -78.7 | 0 | n/a |
| 2023 | -119 | -92.1 | 2.4 | n/a |
| 2024 | -29.4 | -18.3 | 1 | n/a |
| 2025 | -18.2 | -23.5 | not reported | n/a |
How to read this: earnings and margins.
Revenue was $1.2 million in 2012 and $7.1 million in 2024, a compound annual growth rate of 16.1% over 12 years.
Revenue fell 66.0% from 2023 to 2024.
Our estimated free cash flow was -$19.1 million in 2024, a negative margin of 267.3% of revenue, meaning the estimate was below zero. In 2012 the estimated margin was negative 506.8%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2012 | 1.2 | -6 | -506.8% |
| 2013 | 12 | 2.8 | 23.6% |
| 2014 | 3.2 | -17.7 | -555.8% |
| 2015 | 3.8 | -21.5 | -565.2% |
| 2016 | 0.1 | -47.5 | -55276.5% |
| 2017 | 0.9 | -55 | -6036.8% |
| 2018 | 13.5 | -22.5 | -166.9% |
| 2019 | 19.9 | -109 | -550.1% |
| 2020 | 135 | -5.7 | -4.2% |
| 2021 | 23 | -60.2 | -261.4% |
| 2022 | 41.9 | -78.8 | -188.3% |
| 2023 | 21 | -92.6 | -441.8% |
| 2024 | 7.1 | -19.1 | -267.3% |
How to read this: how debt and assets are compared, the current ratio.
In 2025, cash and equivalents were $20.7 million against total liabilities of $11.1 million, or 186.3% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 34.7% of total assets in 2025, compared with 7.6% in 2014, an increase of 27.1 percentage points.
Stockholders equity was $20.9 million in 2025, up from negative equity of -$54.1 million in 2013.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2013 | 18.1 | 12.4 | n/a | -54.1 |
| 2014 | 55.9 | 52.7 | 4.3 | 51.7 |
| 2015 | 111 | 15.1 | 5.9 | 105 |
| 2016 | 63.8 | 12.1 | 13.1 | 50.7 |
| 2017 | 97 | 9.4 | 10.2 | 86.8 |
| 2018 | 191 | 15.1 | 57.2 | 134 |
| 2019 | 233 | 18.3 | 46.2 | 187 |
| 2020 | 271 | 31.7 | 22.2 | 249 |
| 2021 | 247 | 13.5 | 19.5 | 228 |
| 2022 | 182 | 63.7 | 23.5 | 159 |
| 2023 | 126 | 51.8 | 188 | -62.1 |
| 2024 | 35.2 | 31.6 | 126 | -91.1 |
| 2025 | 32.1 | 20.7 | 11.1 | 20.9 |
Positive free cash flow appears in 1 of the 14 fiscal years we hold for Cara Therapeutics from its current SEC filer.
We do not estimate a fair value for Cara Therapeutics while its free cash flow growth is not positive, so there is no value comparison here.
Year-to-year variability in free cash flow is volatile, measured at 77%.
We do not have a dividend yield for Cara Therapeutics.
These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.
How to read this: the price to earnings ratio.
Its trailing P/E ratio is 211% above the average for stocks in the Healthcare sector.
Its trailing P/E ratio is 9% above the average for stocks in the Drug Manufacturers - General industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Cara Therapeutics, limited to companies whose pages we publish. The figures come from our latest data for each company.
| Company | Market cap (USD millions) | P/E | Dividend yield | Cash yield | Price versus our estimate |
|---|---|---|---|---|---|
| Cara Therapeutics (CARA) | - | - | - | - | - |
| Abbott Laboratories (ABT) | 178,390 | 38.4 | 2.4% | 1.9% | 49% above |
| Alkermes plc (ALKS) | 7,552 | - | - | 1.5% | 315% above |
| Amphastar Pharmaceuticals (AMPH) | 1,205 | 13.0 | - | 0.9% | 98% above |
| ANI Pharmaceuticals (ANIP) | 1,558 | 13.9 | - | - | 188% above |
| Bristol-Myers Squibb Company (BMY) | 120,192 | 13.0 | 4.3% | 1.2% | 85% above |
| Collegium Pharmaceutical (COLL) | 768 | 22.7 | - | - | 155% above |
Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.
Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.
Every fiscal year on this page is reported by one SEC filer, CIK 1346830.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: CARA annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does Cara Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to CARA: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
What is the Difference Between Trading Stocks and Investing?
Why Do Companies Perform Stock Buybacks?
How Does Portfolio Churning Affect Your Returns?
How Do Tariffs Affect the Stock Market?
DCA vs Lump Sum: 155 Years of S&P 500 Historical Data
How to Invest $1000 in the Stock Market